Recombinant Sars-Cov Ma15

SARS-CoV-2 IgG ELISA Kit

E4901-100 100 assays
EUR 903.6

Human IgG antibody Laboratories manufactures the recombinant sars-cov ma15 reagents distributed by Genprice. The Recombinant Sars-Cov Ma15 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Recombinant. Other Recombinant products are available in stock. Specificity: Recombinant Category: Sars-Cov Group: Ma15

SARS-CoV Spike Antibody

0.1 mg
EUR 523.7
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Matrix Antibody

0.02 mg
EUR 206.18
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody

0.1 mg
EUR 523.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody

0.02 mg
EUR 206.18
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody

0.1 mg
EUR 523.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Envelope Antibody

0.02 mg
EUR 206.18
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

SARS-CoV Envelope Antibody

0.1 mg
EUR 523.7
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

Ma15 information

SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein

20-192 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein

20-212 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein

20-213 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein

20-214 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein

20-215 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP2 Recombinant Protein

20-217 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP2 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein

20-218 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein

SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein

20-237 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein

20-249 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein

20-250 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein

20-251 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein

20-252 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP2 Recombinant Protein

20-254 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP2 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein

20-255 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein

SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein

97-095 0.1 mg
EUR 821.4
Description: The viral nonstructural protein 1 (nsP1) is the only membrane-associated protein that anchors the replication complex to the cellular membranes. NSP1 inhibits host translation by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome complex further induces an endonucleolytic cleavage near the 5'UTR of host mRNAs, targeting them for degradation. Viral mRNAs are not susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the presence of a 5'-end leader sequence and are therefore protected from degradation. By suppressing host gene expression, nsp1 facilitates efficient viral gene expression in infected cells and evasion from host immune response.

SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein

97-096 0.1 mg
EUR 821.4
Description: During the formation of the coronaviral replication/transcription complex, essential steps include processing of the conserved polyprotein nsp7-10 region by the main protease Mpro and subsequent complex formation of the released nsp's. Upon infecting host cells, coronaviruses assemble a multi-subunit RNA-synthesis complex of viral non-structural proteins (nsp) responsible for the replication and transcription of the viral genome. non-structural proteins 7 (NSP7) forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers.

SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein

97-097 0.1 mg
EUR 821.4
Description: NSP8, forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.